QuantAbundanciaAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

21,036 signal articles · 527 in last 24h · 103,484 total before filter · latest 33m ago
527last 24h
2508last 7d
482● bullish (7d)
256● bearish (7d)
197publishers
AllMacro242Earnings1478M&A140Regulatory16Product4Analyst29
✕ clear all filtersticker: TMDXsentiment: neutralSentiment:bullishneutralbearishshow all (incl. clickbait)
TransMedics Group Q2 Earnings Call Highlights
MarketBeat12h agoneutral
TransMedics Group Q2 Earnings Call Highlights

TransMedics Group (NASDAQ:TMDX) reported record second-quarter revenue as growth in liver procedures, clinical services and transplant logistics offset increased spending on product development, international expansion and infrastructure. Total revenue for the quarter ended June 30 rose 21% year ov

TransMedics (TMDX) Q2 Earnings Lag Estimates
Zacks18h agoneutral
TransMedics (TMDX) Q2 Earnings Lag Estimates

TransMedics (TMDX) delivered earnings and revenue surprises of -12.00% and +3.14%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

TransMedics (TMDX) Q1 2026 Earnings Transcript
Motley Fool91d agoneutral
TransMedics (TMDX) Q1 2026 Earnings Transcript

Waleed Hassanein: Thank you so much, Hannah. As always, joining me today is Gerardo Hernandez, our Chief Financial Officer. Since inception, TransMedics has been relentless in our pursuit to transform organ transplant therapy by increasing utilization of donor organs and improving the clinical outcomes of transplant patients throughout -- through technology and service innovation and by disrupting the status quo.

TransMedics Group Q1 Earnings Call Highlights
MarketBeat91d agoneutral
TransMedics Group Q1 Earnings Call Highlights

TransMedics Group (NASDAQ:TMDX) reported first-quarter 2026 revenue of $174 million, up about 21% year over year and 8% sequentially, as the company continued to expand adoption of its Organ Care System (OCS) platform and its National OCS Program (NOP) logistics model while increasing investment in